Europe

EMA revises policy on conflicts of interest

Friday, November 21, 2014

The EMA has published its revised policy on handling declarations of interests for scientific committee members and experts. The revisions reflect a more balanced approach to handling conflicts of interests that aims to effectively restrict the involvement of experts with possible conflicts of interests in the agency’s work, while maintaining EMA’s ability to access the best available expertise.

[Read More]

Neuro-MAP, MRC Technology to jumpstart drug development for brain diseases

Wednesday, November 19, 2014

Drugs for brain diseases such as dementia, motor neurone disease and Parkinson’s, which have stalled in development, could be revived thanks to up to $47.1 million in funding and resources from a global coalition of charities and funders. The Neurodegeneration Medicines Acceleration Program (Neuro-MAP), led by U.K. medical research charity MRC Technology, will help charities and funding bodies identify promising drug projects no longer in development and help scientists take them forward to the next stage.

[Read More]

Perrigo to acquire Omega Pharma for $4.5 billion

Friday, November 7, 2014

Perrigo, a Dublin, Ireland-based global provider of healthcare products, will acquire Omega Pharma, an OTC healthcare company headquartered in Nazareth, Belgium, for $4.5 billion, including a $3.1 billion purchase price plus assumption of $1.4 billion in debt. The transaction will enhance Perrigo’s OTC product offering and expand its distribution through Omega’s strong established platform. 

[Read More]

EFPIA, Innovative Medicines Initiative form $348.2M Ebola+ program

Friday, November 7, 2014

European Federation of Pharmaceutical Industries and Associations (EFPIA), a representative of the pharmaceutical industry operating in Europe, its specialized group Vaccines Europe and the Innovative Medicines Initiative have launched a $348.2 million call for proposals for an Innovative Medicines Initiative (IMI) program aimed to address the current Ebola crisis. The Ebola+ program will bring together the pharma industry and researchers in a collaborative program aimed to cover the current outbreak, as well as future needs in the space of hemorrhagic fevers.

[Read More]

AstraZeneca, Manchester University form Advanced Drug Delivery Center

Thursday, November 6, 2014

The University of Manchester and AstraZeneca have entered into a strategic collaboration to develop cutting-edge technologies designed to enhance the way drugs work and deliver better health outcomes for patients. Together, they are launching the North West Center for Advanced Drug Delivery, which will be housed in Manchester Pharmacy School and will have links into a wide range of research groups throughout the university.

[Read More]